9amHealth Raises $26M in Series B Funding Led by Define Ventures

The company plans to use the funding to support continued growth and expand its platform to cover more high-cost chronic conditions, which account for a large share of employer pharmacy spending.

Since its founding, 9amHealth has become a leading provider of virtual cardiometabolic care, working with large employers and pharmaceutical companies to support people with obesity, diabetes, high blood pressure, and high cholesterol.

Its care model combines clinical programs, lab testing, medication management, and ongoing support to improve patient outcomes and engagement. The company has also helped reduce pharmacy costs as demand for GLP-1 medications continues to grow.

Building on its existing platform, 9amHealth has already created the clinical systems, care model, and technology needed to manage complex chronic conditions at scale.

These conditions often require expensive speciality medications, ongoing treatments, and coordinated care, making them one of the fastest-growing areas of healthcare costs for employers.

"What makes this possible is our ability to combine specialised clinical care with AI-enabled clinical workflows and personalised member experiences that allow us to scale efficiently across complex chronic conditions," said Frank Westermann, CEO and Co-Founder of 9amHealth. "We've already proven this model in cardiometabolic care, and are now extending to a much broader set of high-cost needs."

Read More:Anomaly Raises Additional $17M in Funding Led by Sound Ventures

"We are proud to partner with 9amHealth at this pivotal stage," said Lynne O'Keefe. "They've demonstrated strong clinical outcomes, and cost savings in one of the fastest growing categories in healthcare. Their platform has the potential to transform how employers manage their most expensive populations."

About 9amHealth

Founded in 2021 by Frank Westermann, Paul Geevarghese, and Anton Kittelberger, 9amHealth is an AI-enabled virtual speciality care platform focused on treating high cost chronic conditions at scale. The company works with employers, health plans and pharmacy benefit managers to provide care for people with obesity, diabetes, hypertension, and dyslipidemia. Members receive access to specialised clinicians, at home lab testing, prescription medications and lifestyle support through a fully integrated virtual care platform.

Read More:Autoimmunity BioSolutions Raises $1M in Seed Extension Funding